Comparison of the safety and efficacy of topical Tacrolimus (0.03%) versus dexamethasone (0.05%) for subepithelial infiltrates after adenoviral conjunctivitis
Authors:
Open Access
- 1 January 2019
- journal article
- research article
- Published by Medknow in Indian Journal Of Ophthalmology
- Vol. 67 (5) , 594-598
Abstract
Purpose: To compare the safety and efficacy of tacrolimus 0.03% ointment with dexamethasone 0.05% ointment for subepithelial infiltrates (SEIs) following adenoviral keratoconjunctivitis (AK). Methods: A randomized, double blind trial was done. Eligibility criteria was corrected distance visual acuity of 6/9 Snellen or worse for at least 4 weeks with corneal SEIs following AK. The grading of SEIs was done on a scale of 0 to 3; 0, no infiltrates, 1 mild infiltration, 2 moderate infiltration and 3, severe infiltration. Consecutive patients with SEIs following AK were randomized to receive either topical tacrolimus 0.03% or dexamethasone 0.05% ointment twice daily for 6 months. Treatment was successful if there was reduction of SEIs and improvement in vision. Results: A total of 45 patients each were assigned to the Tacro and Dexa groups, respectively. Baseline characteristics of patients did not differ significantly (P > 0.001). There was a significant change in symptoms, vision and SEIs in both the groups. However, the magnitude was greater in tacro group. Treatment was successful in 37 (92.5%) patients in Tacro and 34 (85%) patients in dexa group. In dexa group, after a period of 1.24 ± 0.24 months, 7 (15.6%) patients developed a significant rise in intraocular pressure (IOP). Three (7.5%) eyes in tacro and 6 (15%) eyes in dexa group had recurrence of SEIs after cessation of therapy. Conclusion: Tacrolimus 0.03% is an effective alternative to dexamethasone 0.05% with low recurrence rate, no significant rise in IOP but may cause burning and foreign body sensation in some patients.Keywords
This publication has 21 references indexed in Scilit:
- Comparison of clinical outcome with different treatment regimens in acute adenoviral keratoconjunctivitisEye, 2017
- Symptomatic Treatment of Subepithelial Infiltrates after Viral Conjunctivitis: Loteprednol or Dexamethasone?Ocular Immunology and Inflammation, 2016
- Adenoviral keratoconjunctivitisSurvey of Ophthalmology, 2015
- Oral Omega-3 Fatty Acid Treatment for Dry Eye in Contact Lens WearersCornea, 2015
- Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitisBMC Ophthalmology, 2012
- Viral Capsid Is a Pathogen-Associated Molecular Pattern in Adenovirus KeratitisPLOS Pathogens, 2010
- Tacrolimus Ointment 0.03% in the Eye for Treatment of Giant Papillary ConjunctivitisCornea, 2008
- Topical Tacrolimus Ointment for Treatment of Refractory Anterior Segment Inflammatory DisordersCornea, 2005
- Topical Treatment of Acute Adenoviral Keratoconjunctivitis With 0.2% Cidofovir and 1% CyclosporineArchives of Ophthalmology (1950), 2001
- The Clinical Features of Viral Keratitis and a Concept of Their PathogenesisProceedings of the Royal Society of Medicine, 1958